Successful human vaccination by synthetic malarial sporozoite peptides may depend on the choice of an appropriate carrier. Tetanus toxoid (TT) has been proposed because of its safe and widespread use in humans. Paradoxically, however, prior exposure to this toxoid vaccine could produce specific epitopic suppression against synthetic malarial peptides conjugated to this same protein as carrier. Indeed, we have previously reported that such a phenomenon can occur in the case of a synthetic vaccine made with a streptococcal peptide conjugated to TT. Our present study shows that similar results can be observed in mice preimmunized with TT 1 month before the administration of a conjugate containing TT and a Plasmodium knowlesi peptide. Analysis of the isotypic pattern of the antipeptide response showed that the immunoglobulin Gl (IgGl) subclass and especially the IgG2a and IgG2b subclasses were suppressed. In contrast, when a sporozoite peptide from Plasmodiumfalciparum was coupled to TT, the total antipeptide antibodies and particularly the IgGI subclass were enhanced by preimmunization by TT. This increase of antipeptide antibodies was correlated with a greater ability of the sera to neutralize sporozoite infectivity. These results indicate that prior exposure to TT does not systematically impair the antibody response against a peptide administered as a peptide-TT conjugate.
Protective immunity against malaria in animals and humans was first obtained by immunization with irradiated sporozoites. The use of a natural structure to obtain a vaccine is not being considered because sufficient amounts of antigens cannot be produced. Two substitutes for natural vaccines are presently being studied: recombinant DNA technology and peptide synthesis.
Protective antibodies produced in animals and human volunteers immunized with irradiated sporozoites are directed against a surface protein called circumsporozoite protein (CSP) (6, 12, 19) . Such antibodies recognized a single immunodominant region of the protein (25) formed by tandem repeated sequences of 12 amino acids (QAQGDGAN AGQP) in Plasmodium knowlesi (10, 22) and of 4 amino acids (NANP) in Plasmodium falciparum (7, 11) . Synthetic peptides representing these repetitive regions conjugated to carriers are capable of producing biologically active antibodies (2, 5, 13, 18) . In most cases, tetanus toxoid (TT) was chosen as a carrier because of its extensive use in humans. However, preexposure to this toxoid could induce a specific epitopic suppression against the hapten in subjects immunized later with hapten-TT conjugate vaccines. Indeed this specific epitopic suppression, first described by Herzenberg et al. (15) , was also observed in the case of synthetic vaccine models (24) such as a streptococcal SCB7 (for synthetic cyanogen bromide fragment no. 7) peptide (4) (24) . All these peptides were synthetized by a solid-phase method (16) .
Preparation of peptide-carrier conjugates. Conjugates were prepared by a method described previously (1) . Briefly, each peptide was coupled by glutaraldehyde via its NH2 group to TT. The coupling reaction was carried out at 20°C in phosphate-buffered saline, pH 7.35, by mixing the peptide to the carrier protein at a molar ratio of 40:1 and adding 1 volume of glutaraldehyde at 2.63 mM. The reaction was allowed to proceed for 6 days with constant stirring, followed by dialysis against phosphate-buffered saline.
Analysis of amino acid composition of the conjugates.
Amino acid analysis was performed after acid hydrolysis with a Beckman amino acid analyzer. Recognition of the natural structure and biological activity of antibodies. Antibodies reacting with P. falciparum sporozoite surface antigens were measured by an immunofluorescence assay, with, as previously described (9) , wet preparations of sporozoites attached to poly-L-treated glass slides. Anti-(NANP)4 antibodies were also measured by inhibition of P. falciparum sporozoite penetration in cultured cells. Quantitative tests were performed as previously described (18) . Human (14) . These differences were shown to be statistically significant by individually titrating the sera collected on day 37. In both cases epitopic suppression was not linked to a reduction of the antibody response against the carrier. Indeed, on day 21 anti-TT antibodies of TT-primed mice were markedly increased (121,400 for SCB7-TT and 19,800 for PK26-TT) compared with those of nonprimed mice (55,800 and 8,300, respectively). In contrast, preimmunization with carrier did not inhibit the response to (NANP)4. Indeed, the antipeptide titers were more elevated after preimmunization with 100 ,ug of TT. Absence of epitopic suppression was also observed when the (NANP)4-TT conjugate was administrated with Freund complete adjuvant in place of aluminum hydroxide. Sera of TT-primed mice immunized with the (NANP)4-TT conjugate contained higher levels of antibodies to sporozoites, as measured by the immunofluorescence antibody test. They were also shown to be more biologically active, as measured by inhibition of penetration of sporozoites into human hepatocytes ( Table 2 ). In most experiments, 100 ptg of TT was used for preimmunization. However, when mice were pretreated with 10 jig of TT, suppression of antibody responses to SCB7-TT and PK26-TT and enhancement of (NANP)4-TT were also observed (data not shown).
Influence of TT priming on IgG subclasses of antipeptide antibodies. Preimmunization by TT may also influence the IgG subclasses of antipeptide antibodies. Results in Table 3 confirm that in the case of SCB7 and PK26, total IgG was decreased, whereas it was increased in the case of (NANP)4. These data also show that with the first two peptides, all the IgG isotypes measured were suppressed (approximately 40% for the IgGl subclass and 95 to 100% for IgG2a and IgG2b). In contrast, mice immunized with (NANP)4-TT in aluminum hydroxide or Freund complete adjuvant had a marked enhancement of the IgGl subclass (threefold increase). Such an effect was weaker and less defined for the IgG2a and IgG2b subclasses, especially in animals in which aluminum hydroxide was used as an adjuvant.
DISCUSSION
Experiments described in this report were performed to investigate whether epitope-specific suppression could compromise the use of TT as a carrier in vaccines containing synthetic malarial peptides. Previous observations had shown that preimmunization with TT inhibited the subsequent antibody response against a streptococcal peptide conjugated to the same carrier (24) . Data presented here show that similar results can be obtained with a simian malarial sporozoite peptide (PK26) conjugated to TT. Surprisingly, however, preimmunization of Swiss mice with TT did not inhibit the response but rather enhanced antibody production to a human malarial sporozoite peptide, (NANP)4, conjugated under the same conditions. Antibodies were measured by ELISA, immunofluorescence, and inhibition of penetration of sporozoites into hepatocytes. The last method is considered to be correlated with the presence of protective antibodies (18) .
Analysis of the isotypic pattern of anti-SCB7 and anti-PK26 antibodies showed that the decrease in total IgG was correlated with suppression of the three isotypes measured, especially IgG2a and IgG2b as previously reported by Herzenberg et al. (14) . It 
